BioSpace News Archive

SightGlass Vision, Inc., a clinical-stage life sciences company focused on ending nearsightedness, announced topline results from a planned 12-month interim analysis of the Company’s pivotal trial evaluating its novel eyeglasses designed to slow the progression of myopia in children.

Menlo Therapeutics Inc. announced that its wholly-owned subsidiary, Foamix Pharmaceuticals Ltd. has entered into a settlement and license agreement to resolve the remaining pending patent litigation involving Finacea® Foam.

Intra-Cellular Therapies, Inc., a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system disorders, announced it has successfully initiated its promotional activities associated with the launch of CAPLYTA.

Bioanalytical methods developed and validated for its clinical trials. Tetra initiates study to quantify phytocannabinoid metabolites and precursors and minor phytocannabinoids in human plasma. OTTAWA, April 02, 2020 (GLOBE NEWSWIRE) -- Tetra Bio-Pharma Inc . (“ Tetra ” or the “ Company ”) (TSX-V:TBP) (OTCQB:TBPMF), a leader in cannabinoid-derived drug discovery and development, is pleased to announce the launch of a study to determine the levels of cannabinoid metabolites (e.g., 7-CO

Paratek Pharmaceuticals, Inc. today announced that the Biomedical Advanced Research and Development Authority (BARDA) has initiated funding to support all of the U.S. Food and Drug Administration (FDA) post-mar

Believes Stockholders Sent a Loud and Clear Message at Special Meeting That They Oppose This Value-Destructive Combination

Geron Corporation announced an update to information from its March 12 year-end conference call related to the impact of the COVID-19 pandemic on the Company’s business, and described the measures being taken to protect the safety of Geron’s employees and patients in its clinical trials.

AbbVie, a research-based global biopharmaceutical company, will announce its first-quarter 2020 financial results on Friday, May 1, 2020, before the market opens.

Daniel Alain, Inc. (“Daniel Alain”) announced today it has acquired a stake in Applied Biology

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced its joint venture entity with Voltron Therapeutics, Inc., HaloVax, has entered into a Sponsored Research Agreement with the Vaccine and Immunotherapy Center (VIC) of the Massachusetts General Hospital (MGH).